Testosterone Enanthate
FDA-approved product (injectable, injection), marketed as Delatestryl, Testosterone Enanthate, Xyosted (Autoinjector).
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 1 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Cancer
- Hypogonadism
- Hypogonadotropic hypogonadism
- Klinefelter's syndrome
- Neoplasm
- Orchitis
- Physiological sexual disorder
- Sexual dysfunction
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- 3-oxoandrosten (4) derivatives
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.
AI-predicted activity
AI prediction · nothing measured- MRSA51.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli28.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae27.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis24.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Testosterone Enanthate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Trimetrexate GlucuronateExisting use: Other agents against amoebiasis and other protozoal diseases88.6% AI-predicted activityagainst E. coliLab records exist17 registered studies
- Folic AcidExisting use: Acne, Anemia, Anemia (phenotype) and 8 more87.0% AI-predicted activityagainst E. coliLab records exist50+ registered studies
- MethotrexateExisting use: Acute lymphoblastic leukemia, Adenoma, Arthritis and 21 more86.8% AI-predicted activityagainst E. coliLab records exist50+ registered studies
- PralatrexateExisting use: Cancer, Mature T-cell and NK-cell non-Hodgkin lymphoma, Neoplasm and 2 more82.2% AI-predicted activityagainst E. coli44 registered studies
- TriclosanExisting use: Phenol and derivatives, Medicated dressings with antiinfectives81.0% AI-predicted activityagainst E. coliLab records exist50+ registered studies
- Leucovorin CalciumExisting use: Osteosarcoma67.6% AI-predicted activityagainst E. coli50+ registered studies
- LevoleucovorinExisting use: Anemia, Colorectal adenocarcinoma, Colorectal cancer and 3 more67.6% AI-predicted activityagainst E. coli50+ registered studies
- PyrimethamineExisting use: Malaria, Toxoplasmosis64.6% AI-predicted activityagainst E. coliLab records exist50+ registered studies
- Copanlisib DihydrochlorideExisting use: Follicular lymphoma, Neoplasm, Neoplasm of mature B-cells63.5% AI-predicted activityagainst E. coli10 registered studies
- AfamelanotideExisting use: Erythropoietic protoporphyria62.6% AI-predicted activityagainst E. coli23 registered studies
- Rimegepant SulfateExisting use: Migraine disorder61.6% AI-predicted activityagainst E. coli50+ registered studies
- Histrelin AcetateExisting use: Neoplasm, Prostate adenocarcinoma, Prostate cancer61.6% AI-predicted activityagainst E. coli13 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Feasibility Study of Post-hospitalization Interventions to Improve Physical Function in Older Adults
NCT02203656 · start 2013-10
Registered record
- Registry ID
- NCT02203656
- Conditions
- Aging
- Interventions
- Placebo; Nutritional Supplement; In-home exercise; Testosterone
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2013-10
- Completion
- 2017-12
- Enrolment
- 113
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAgingInterventionPlacebo; Nutritional Supplement; In-home exercise; TestosteronePhasePhase 1Registry statusCompletedPharmacokinetic Study of Testosterone Enanthate
NCT01887418 · start 2013-09
Registered record
- Registry ID
- NCT01887418
- Conditions
- Hypogonadism
- Interventions
- QuickShot™ - 50 mg Treatment B; QuickShot™ - 100 mg Treatment A; Delatestryl 200 mg IM Treatment C
- Study type
- INTERVENTIONAL
- Phase
- Phase 1 / Phase 2
- Registry status
- Completed
- Start
- 2013-09
- Completion
- 2014-01
- Enrolment
- 39
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypogonadismInterventionQuickShot™ - 50 mg Treatment B; QuickShot™ - 100 mg Treatment A; Delatestryl 200 mg IM Treatment CPhasePhase 1 / Phase 2Registry statusCompletedImpact of Estradiol Addback
NCT01862835 · start 2013-05
Registered record
- Registry ID
- NCT01862835
- Conditions
- Normal Healthy Volunteers
- Interventions
- Degarelix; Testosterone; Anastrozole; Estrogen patch
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2013-05
- Completion
- 2018-12-30
- Enrolment
- 43
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionNormal Healthy VolunteersInterventionDegarelix; Testosterone; Anastrozole; Estrogen patchPhasePhase 1Registry statusCompletedOral Testosterone for the Treatment of Hypogonadism
NCT01717768 · start 2012-10
Registered record
- Registry ID
- NCT01717768
- Conditions
- Hypogonadism
- Interventions
- TSX-002
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2012-10
- Completion
- 2014-12
- Enrolment
- 130
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypogonadismInterventionTSX-002PhasePhase 2Registry statusCompletedTestosterone Administration and ACL Reconstruction in Men
NCT01595581 · start 2012-04
Registered record
- Registry ID
- NCT01595581
- Conditions
- Muscle Atrophy; ACL Reconstruction; Trauma; Osteoarthritis
- Interventions
- Testosterone; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2012-04
- Completion
- 2015-05
- Enrolment
- 14
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMuscle Atrophy; ACL Reconstruction; Trauma; OsteoarthritisInterventionTestosterone; PlaceboPhasePhase 3Registry statusCompletedOptimizing Protein Intake in Older Americans With Mobility Limitations
NCT01275365 · start 2011-05
Registered record
- Registry ID
- NCT01275365
- Conditions
- Mobility Limitation
- Interventions
- Testosterone enanthate; Testosterone enanthate
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2011-05
- Completion
- 2017-01-19
- Enrolment
- 92
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMobility LimitationInterventionTestosterone enanthate; Testosterone enanthatePhasePhase 3Registry statusCompletedTestosterone Replacement for Fatigue in Male Hypogonadic Advanced Cancer Patients
NCT00965341 · start 2009-09
Registered record
- Registry ID
- NCT00965341
- Conditions
- Advanced Cancer
- Interventions
- Testosterone; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2009-09
- Completion
- 2012-09
- Enrolment
- 53
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAdvanced CancerInterventionTestosterone; PlaceboPhasePhase 3Registry statusCompletedTestosterone for Treating Cachexia in Patients With Squamous Cell Carcinoma
NCT00878995 · start 2009-06-03
Registered record
- Registry ID
- NCT00878995
- Conditions
- Cachexia; Squamous Cell Carcinoma
- Interventions
- Placebo Testosterone; Testosterone Enanthate 100 MG/ML
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2009-06-03
- Completion
- 2015-06
- Enrolment
- 28
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCachexia; Squamous Cell CarcinomaInterventionPlacebo Testosterone; Testosterone Enanthate 100 MG/MLPhasePhase 1Registry statusCompletedAnabolic and Inflammatory Responses to Short-Term Testosterone Administration in Older Men
NCT00957801 · start 2009-03
Registered record
- Registry ID
- NCT00957801
- Conditions
- Sarcopenia
- Interventions
- Testosterone injection; Testosterone gel; Medrol
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2009-03
- Completion
- 2015-12
- Enrolment
- 29
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSarcopeniaInterventionTestosterone injection; Testosterone gel; MedrolPhasePhase 4Registry statusCompletedPharmacokinetic Study of Oral Testosterone (T) Ester Formulations in Hypogonadal Men
NCT00695110 · start 2008-06
Registered record
- Registry ID
- NCT00695110
- Conditions
- Hypogonadism
- Interventions
- Oral testosterone undecanoate (TU) (300 mg T equivalents/dose); Oral testosterone undecanoate (TU) combined with testosterone enanthate (TE) (400 mg T equivalents/dose); Oral testosterone undecanoate (TU) (200 mg T equivalents/dose with and without food); Oral testosterone undecanoate (TU) combined with testosterone enanthate (TE) (300 mg T equivalents/dose)
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2008-06
- Completion
- 2009-08
- Enrolment
- 29
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypogonadismInterventionOral testosterone undecanoate (TU) (300 mg T equivalents/dose); Oral testosterone undecanoate (TU) combined with testosterone enanthate (TE) (400 mg T equivalents/dose); Oral testosterone undecanoate (TU) (200 mg T equivalents/dose with and without food); Oral testosterone undecanoate (TU) combined with testosterone enanthate (TE) (300 mg T equivalents/dose)PhasePhase 2Registry statusCompletedEffects of Medications in Patients With Hypogonadism
NCT01601327 · start 2008-01
Registered record
- Registry ID
- NCT01601327
- Conditions
- Idiopathic Hypogonadotropic Hypogonadism
- Interventions
- Testosterone enanthate (Sustanon 250 mg); Human chorionic gonadotropin (hCG) (Pregnyl 5000 IU); Testosteron gel (Testojel 50 mg)
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2008-01
- Completion
- 2012-03
- Enrolment
- 119
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionIdiopathic Hypogonadotropic HypogonadismInterventionTestosterone enanthate (Sustanon 250 mg); Human chorionic gonadotropin (hCG) (Pregnyl 5000 IU); Testosteron gel (Testojel 50 mg)PhasePhase 4Registry statusCompletedPilot Pharmacokinetic Study of Oral Testosterone Ester Formulations in Hypogonadal Men
NCT02697188 · start 2007-11
Registered record
- Registry ID
- NCT02697188
- Conditions
- Hypogonadism
- Interventions
- Testosterone undecanoate; Testosterone enanthate
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2007-11
- Completion
- 2008-04
- Enrolment
- 12
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypogonadismInterventionTestosterone undecanoate; Testosterone enanthatePhasePhase 2Registry statusCompletedSafety and Tolerability of MK0773 in Healthy Older Men (0773-004)
NCT01017458 · start 2007-06
Registered record
- Registry ID
- NCT01017458
- Conditions
- Healthy
- Interventions
- MK0773; Comparator: testosterone enanthate; Comparator: placebo oral tablet; Comparator: placebo injection
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2007-06
- Completion
- 2008-08
- Enrolment
- 68
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthyInterventionMK0773; Comparator: testosterone enanthate; Comparator: placebo oral tablet; Comparator: placebo injectionPhasePhase 1Registry statusCompleted5-Alpha Reductase and Anabolic Effects of Testosterone
NCT00475501 · start 2007-01
Registered record
- Registry ID
- NCT00475501
- Conditions
- Male Hypogonadism; Muscle Atrophy; Sarcopenia; Benign Prostate Hypertrophy
- Interventions
- Testosterone Enanthate; Finasteride; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2007-01
- Completion
- 2014-10
- Enrolment
- 60
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMale Hypogonadism; Muscle Atrophy; Sarcopenia; Benign Prostate HypertrophyInterventionTestosterone Enanthate; Finasteride; PlaceboPhasePhase 2Registry statusCompletedCycled Testosterone Replacement Study
NCT00957528 · start 2006-01
Registered record
- Registry ID
- NCT00957528
- Conditions
- Hypogonadism
- Interventions
- Testosterone; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2006-01
- Completion
- 2008-12
- Enrolment
- 26
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypogonadismInterventionTestosterone; PlaceboPhasePhase 1Registry statusCompleted